Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease

Mutsuko Muraki, Taisei Mikami, Mayumi Kitaguchi, Tomoko Sugawara, Katsuyoshi Isonishi, Sadao Kaneko, Takeshi Kashiwaba, Fumio Moriwaka, Satoshi Yamada, Hisao Onozuka, Hiroyuki Tsutsui

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background. Pergolide mesilate is widely used to treat Parkinson's disease in both the USA and Japan, but the maintenance dose is distinctly different between the USA (usually more than 1.5 mg/day) and Japan (usually less than 1.5 mg/day). Although several reports from the USA have suggested that mitral, aortic, and tricuspid valvular lesions were caused by pergolide, it is unclear whether low-dose pergolide therapy causes such valvular lesions. Objectives. The effects of low-dose pergolide therapy on cardiac valves were studied in Japanese patients with Parkinson's disease. Methods. One hundred and five consecutive patients with Parkinson's disease approved for our protocol were enrolled in this study. Forty patients were treated with low-dose pergolide (0.05-1.5 mg/day for 2-115 months), and were included in the pergolide group (mean age 71 ± 6 years). The other 44 patients received no ergot-derived dopamine receptor agonists, and 32 patients acted as age-matched controls (mean age 71 ± 7 years). Both groups of patients underwent echocardiographic examination to detect organic lesions in cardiac valves such as thickening of the leaflet, annular calcification, restriction of valve motion and valvular tenting, and valvular regurgitation greater than 2 + on the 4-point scale. Results. No significant difference was observed in the incidence of aortic, mitral and pulmonic valve lesions between the pergolide group and the control group. Although no organic lesions were detected in the tricuspid valve, the incidence of tricuspid regurgitation was significantly higher in the pergolide group than in the control group (p < 0.05). Conclusions. Although low-dose pergolide of less than 1.5 mg/day does not cause serious damage in the left-sided valves, it may induce tricuspid regurgitation.

Original languageEnglish
Pages (from-to)221-227
Number of pages7
JournalJournal of Cardiology
Volume46
Issue number6
Publication statusPublished - Dec 1 2005
Externally publishedYes

Fingerprint

Pergolide
Heart Valves
Parkinson Disease
Tricuspid Valve Insufficiency
Therapeutics
Japan
Control Groups
Mesylates
Tricuspid Valve
Incidence
Dopamine Agonists
Mitral Valve
Age Groups

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Muraki, M., Mikami, T., Kitaguchi, M., Sugawara, T., Isonishi, K., Kaneko, S., ... Tsutsui, H. (2005). Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease. Journal of Cardiology, 46(6), 221-227.

Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease. / Muraki, Mutsuko; Mikami, Taisei; Kitaguchi, Mayumi; Sugawara, Tomoko; Isonishi, Katsuyoshi; Kaneko, Sadao; Kashiwaba, Takeshi; Moriwaka, Fumio; Yamada, Satoshi; Onozuka, Hisao; Tsutsui, Hiroyuki.

In: Journal of Cardiology, Vol. 46, No. 6, 01.12.2005, p. 221-227.

Research output: Contribution to journalArticle

Muraki, M, Mikami, T, Kitaguchi, M, Sugawara, T, Isonishi, K, Kaneko, S, Kashiwaba, T, Moriwaka, F, Yamada, S, Onozuka, H & Tsutsui, H 2005, 'Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease', Journal of Cardiology, vol. 46, no. 6, pp. 221-227.
Muraki M, Mikami T, Kitaguchi M, Sugawara T, Isonishi K, Kaneko S et al. Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease. Journal of Cardiology. 2005 Dec 1;46(6):221-227.
Muraki, Mutsuko ; Mikami, Taisei ; Kitaguchi, Mayumi ; Sugawara, Tomoko ; Isonishi, Katsuyoshi ; Kaneko, Sadao ; Kashiwaba, Takeshi ; Moriwaka, Fumio ; Yamada, Satoshi ; Onozuka, Hisao ; Tsutsui, Hiroyuki. / Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease. In: Journal of Cardiology. 2005 ; Vol. 46, No. 6. pp. 221-227.
@article{5cb7867296e840fca3c756fdc648ad79,
title = "Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease",
abstract = "Background. Pergolide mesilate is widely used to treat Parkinson's disease in both the USA and Japan, but the maintenance dose is distinctly different between the USA (usually more than 1.5 mg/day) and Japan (usually less than 1.5 mg/day). Although several reports from the USA have suggested that mitral, aortic, and tricuspid valvular lesions were caused by pergolide, it is unclear whether low-dose pergolide therapy causes such valvular lesions. Objectives. The effects of low-dose pergolide therapy on cardiac valves were studied in Japanese patients with Parkinson's disease. Methods. One hundred and five consecutive patients with Parkinson's disease approved for our protocol were enrolled in this study. Forty patients were treated with low-dose pergolide (0.05-1.5 mg/day for 2-115 months), and were included in the pergolide group (mean age 71 ± 6 years). The other 44 patients received no ergot-derived dopamine receptor agonists, and 32 patients acted as age-matched controls (mean age 71 ± 7 years). Both groups of patients underwent echocardiographic examination to detect organic lesions in cardiac valves such as thickening of the leaflet, annular calcification, restriction of valve motion and valvular tenting, and valvular regurgitation greater than 2 + on the 4-point scale. Results. No significant difference was observed in the incidence of aortic, mitral and pulmonic valve lesions between the pergolide group and the control group. Although no organic lesions were detected in the tricuspid valve, the incidence of tricuspid regurgitation was significantly higher in the pergolide group than in the control group (p < 0.05). Conclusions. Although low-dose pergolide of less than 1.5 mg/day does not cause serious damage in the left-sided valves, it may induce tricuspid regurgitation.",
author = "Mutsuko Muraki and Taisei Mikami and Mayumi Kitaguchi and Tomoko Sugawara and Katsuyoshi Isonishi and Sadao Kaneko and Takeshi Kashiwaba and Fumio Moriwaka and Satoshi Yamada and Hisao Onozuka and Hiroyuki Tsutsui",
year = "2005",
month = "12",
day = "1",
language = "English",
volume = "46",
pages = "221--227",
journal = "Journal of cardiography. Supplement",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",
number = "6",

}

TY - JOUR

T1 - Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease

AU - Muraki, Mutsuko

AU - Mikami, Taisei

AU - Kitaguchi, Mayumi

AU - Sugawara, Tomoko

AU - Isonishi, Katsuyoshi

AU - Kaneko, Sadao

AU - Kashiwaba, Takeshi

AU - Moriwaka, Fumio

AU - Yamada, Satoshi

AU - Onozuka, Hisao

AU - Tsutsui, Hiroyuki

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Background. Pergolide mesilate is widely used to treat Parkinson's disease in both the USA and Japan, but the maintenance dose is distinctly different between the USA (usually more than 1.5 mg/day) and Japan (usually less than 1.5 mg/day). Although several reports from the USA have suggested that mitral, aortic, and tricuspid valvular lesions were caused by pergolide, it is unclear whether low-dose pergolide therapy causes such valvular lesions. Objectives. The effects of low-dose pergolide therapy on cardiac valves were studied in Japanese patients with Parkinson's disease. Methods. One hundred and five consecutive patients with Parkinson's disease approved for our protocol were enrolled in this study. Forty patients were treated with low-dose pergolide (0.05-1.5 mg/day for 2-115 months), and were included in the pergolide group (mean age 71 ± 6 years). The other 44 patients received no ergot-derived dopamine receptor agonists, and 32 patients acted as age-matched controls (mean age 71 ± 7 years). Both groups of patients underwent echocardiographic examination to detect organic lesions in cardiac valves such as thickening of the leaflet, annular calcification, restriction of valve motion and valvular tenting, and valvular regurgitation greater than 2 + on the 4-point scale. Results. No significant difference was observed in the incidence of aortic, mitral and pulmonic valve lesions between the pergolide group and the control group. Although no organic lesions were detected in the tricuspid valve, the incidence of tricuspid regurgitation was significantly higher in the pergolide group than in the control group (p < 0.05). Conclusions. Although low-dose pergolide of less than 1.5 mg/day does not cause serious damage in the left-sided valves, it may induce tricuspid regurgitation.

AB - Background. Pergolide mesilate is widely used to treat Parkinson's disease in both the USA and Japan, but the maintenance dose is distinctly different between the USA (usually more than 1.5 mg/day) and Japan (usually less than 1.5 mg/day). Although several reports from the USA have suggested that mitral, aortic, and tricuspid valvular lesions were caused by pergolide, it is unclear whether low-dose pergolide therapy causes such valvular lesions. Objectives. The effects of low-dose pergolide therapy on cardiac valves were studied in Japanese patients with Parkinson's disease. Methods. One hundred and five consecutive patients with Parkinson's disease approved for our protocol were enrolled in this study. Forty patients were treated with low-dose pergolide (0.05-1.5 mg/day for 2-115 months), and were included in the pergolide group (mean age 71 ± 6 years). The other 44 patients received no ergot-derived dopamine receptor agonists, and 32 patients acted as age-matched controls (mean age 71 ± 7 years). Both groups of patients underwent echocardiographic examination to detect organic lesions in cardiac valves such as thickening of the leaflet, annular calcification, restriction of valve motion and valvular tenting, and valvular regurgitation greater than 2 + on the 4-point scale. Results. No significant difference was observed in the incidence of aortic, mitral and pulmonic valve lesions between the pergolide group and the control group. Although no organic lesions were detected in the tricuspid valve, the incidence of tricuspid regurgitation was significantly higher in the pergolide group than in the control group (p < 0.05). Conclusions. Although low-dose pergolide of less than 1.5 mg/day does not cause serious damage in the left-sided valves, it may induce tricuspid regurgitation.

UR - http://www.scopus.com/inward/record.url?scp=30344481661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344481661&partnerID=8YFLogxK

M3 - Article

C2 - 16389741

AN - SCOPUS:30344481661

VL - 46

SP - 221

EP - 227

JO - Journal of cardiography. Supplement

JF - Journal of cardiography. Supplement

SN - 0914-5087

IS - 6

ER -